In addition, the KRAS-driven non-classical Gln metabolic pathway proceeds through arginine methylase 1 (CARM1)-mediated MDH1 methylation, which is inhibited to regulate oxidative stress and ultimately to meet the changing metabolic demands of tumor cells (38). Here, KRAS is linked to neoplasm.